At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed prostate adenocarcinoma
- ✓Clinical stage T1c or T2 (stage II)
- ✓Gleason score 6 or 7 on initial biopsy
- ✓PSA <10 ng/mL within past 3 months
- ✕Prior hormonal agents (including dutasteride or finasteride) within 6 months
- ✕Prior chemotherapy within 6 months
- ✕Prior radiotherapy for the primary tumor
- ✕Concurrent antiandrogen therapy, dutasteride, finasteride, or dehydroepiandrosterone/phytoestrogen supplements
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Controlled Trial Evaluating the Tissue Effects of Preoperative Finasteride Versus Placebo for Patients With Clinically Organ-Confined Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Finasteride, Placebo, and 2 other interventions for Adenocarcinoma of the Prostate and Stage II Prostate Cancer. Completed, enrolled 204 participants across 8 sites.
Detailed Summary
This randomized phase II trial studies how well finasteride works in treating patients with stage II prostate cancer who are undergoing surgery. Testosterone can cause the growth of prostate cancer cells. Hormone therapy using finasteride may fight prostate cancer by lowering the amount of testosterone the body makes. Giving finasteride before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Study Details
Timeline
Interventions
Given PO
Given PO
Undergo prostatectomy
Correlative studies